Glatiramer Completed Phase 4 Trials for Coronavirus Disease 2019 (COVID‑19) / Relapsing Multiple Sclerosis (RMS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT04878211A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab